Today’s stock pick update

Learn More

FREE TRAINING: TRADERSPRO PRESENTS Retire In 18 Months With $2.4 Million?  37 year old trader uses this “unconventional” strategy to turn $10K into $2.4 million in only 18 months. Another trader turned $5K into $15 million and still another turned $30K into $80 million. Click here to discover their millionaire maker strategy

Amazon Shares Drop After Q2 Revenue Miss Amazon is on track for its worst day since March 2020, and is down 7% at the time of writing. The drop in the stock comes after Amazon missed on revenue expectations for the second quarter, reporting revenue of $113.08 billion versus estimates for a reading of $115.2 billion. Amazon also warned that it expects to see slower growth for the next few quarters versus year-over-year comparisons to its business amid COVI... Read More Align Technology (NASDAQ: ALGN): Align shares gained as much as 9.76% yesterday after the company announced second quarter earnings results. “Overall, we are very pleased with our second-quarter results and our continued strong performance across regions, customer channels, and products. While there continues to be uncertainty around the pandemic and increasing restrictions related to COVID-19 in... Read More IBKR is down -22.5% from its March high – you should be paying attention It seems clear that consumers have been anxious for an outlet to more than a year’s worth of pent-up, stay-at-home anxiety, which I think is why there have been pretty significant rebounds over the last few months in social gathering and travel-related economic activity. That’s a positive for industries like travel, hospitality, and the economy at large – but it could also act as a drag on results for the companies that have serviced savings and investment accounts over the past yea... Read More

Featured Stock Celldex Therapeutics, Inc. (CLDX) – Buy Price: $46.50 or better Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. Read More

Trend Following Picks Celldex Therapeutics, Inc. (CLDX) – Buy Price: $46.50 or better Roku, Inc. (ROKU) – Buy Price: $475.00 or better Capital One Financial Corporation (COF) – Buy Price: $165.00 or better Summit Midstream Partners, LP (SMLP) – Buy Price: $40.00 or better Alcoa Corporation (AA) – Buy Price: $40.00 or better All Picks

Reversal Picks Blue Apron Holdings, Inc. (APRN) Buy Target $4.75 Sell Target $5.49 Auddia Inc. (AUUD) Buy Target $5.33 Sell Target $6.85 Glory Star New Media Group Holdings Limited (GSMG) Buy Target $3.01 Sell Target $3.65 Code Chain New Continent Limited (CCNC) Buy Target $2.43 Sell Target $2.87 Second Sight Medical Products, Inc. (EYES) Buy Target $5.26 Sell Target $6.37 All Picks

Low Price Stock Picks Celsion Corporation (CLSN) Nymox Pharmaceutical Corporation (NYMX) Drone Delivery Canada Corp. (TAKOF) Integrated Ventures, Inc. (INTV) AIkido Pharma Inc. (AIKI) All Picks

Already subscribed to our premium service? Click here to Login Not a TradersPro subscriber yet? Learn More About TradersPro Here - Learn The # 1 Key To Successful Stock Investing Profits

 

This email was sent to phanhoa1821960.trader@blogger.com  from Investiv, LLC 265 N. Main | Ste. D #283 Kaysville | UT | 84037  Unsubscribe  Disclaimers, Terms & Conditions | Privacy Policy Copyright 2020  Investing is Inherently Risky - There are risks inherent in all investments, which may make such investments unsuitable for certain persons. These include, for example, economic, political, currency exchange, rate fluctuations, and limited availability of information on international securities. You may lose all of your money trading and investing. Do NOT enter any trade without fully understanding the worst-case scenarios of that trade. And do NOT trade with money you cannot afford to lose. Past performance of an investment is not necessarily indicative of its future results. No assurance can be given that any implied recommendation will be profitable or will not be subject to losses.